ESR1 and prostate cancer: Both in vitro and in vivo studies have demonstrated that estrogen receptor α (ERα)+ CAFs exert a suppressive effect on macrophage migration in prostate cancer (PCa) by inhibiting CCL5, as well as reducing IL-6 secretion, which attenuates invasiveness.